The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Garrison, Louis P., Wang, Si-Tien, Huang, Hui, Ba-Mancini, Abbie, Shi, Hongliang, Chen, Kristina, Korves, Caroline, Dhawan, Ravinder, Cakana, Andrew, van de Velde, Helgi, Corzo, Deyanira, Duh, Mei Sheng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2013
Gaiak:
Economics of Oncology Practice
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556252/
https://ncbi.nlm.nih.gov/pubmed/23299777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0380
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak